IPH-6501, a CD20-targeting antibody-based NK-cell engager therapeutic for the treatment of B-NHL
June 19, 2023
Researchers from Innate Pharma SA recently presented preclinical data for IPH-6501, a novel CD20-targeting tetraspecific antibody-based natural killer (NK)-cell engager therapeutic being developed for the treatment of patients with B-cell non-Hodgkin lymphoma (B-NHL).